Surgery for Lung Cancer
(SAVED LUNG Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether individuals with certain types of lung cancer can safely skip surgery after responding well to initial treatments like chemotherapy and immunotherapy. Researchers aim to determine if simply observing patients is as effective as standard-of-care surgery, with a focus on safety and future health outcomes. Those with Stage II-III non-small cell lung cancer with specific characteristics and no recent serious infections might find this trial suitable. Participants will either undergo surgery with regular follow-ups or receive regular follow-ups without surgery to compare results. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this innovative approach.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that lung surgery can yield varying results. Studies indicate that complications occur in 25% to 40% of cases, meaning about one in four to two in five patients might experience issues post-surgery. However, patients tend to recover better and face fewer problems with a more experienced surgeon.
This trial is in its early stages, focusing primarily on safety. The treatment is still under testing, and researchers will closely monitor for any side effects or complications.
Prospective participants should discuss joining this trial with their healthcare provider. Providers can offer more information and help assess the benefits and risks based on individual health.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores the potential of managing lung cancer with observation instead of immediate surgery. The unique approach involves close surveillance using regular low-dose CT scans and ctDNA testing to monitor the cancer's status without surgical intervention. This method could lead to less invasive management for patients, reducing the risks and recovery time associated with surgery. By comparing this observational protocol to standard surgical treatment, researchers aim to determine if some patients can safely avoid surgery, potentially transforming how lung cancer is managed in the future.
What data supports the effectiveness of the treatment Observation without surgery, Standard-of-care surgery for lung cancer?
Research shows that surgical resection (removal of cancerous tissue) is the main way to cure non-small cell lung cancer (NSCLC), and improving the quality of surgery can lead to better survival rates. High-volume centers, which perform more surgeries, tend to have better outcomes, suggesting that following best surgical practices can improve results.
Who Is on the Research Team?
Antoine Desilets, MD, MSc
Principal Investigator
Centre hospitalier de l'Université de Montréal (CHUM)
Are You a Good Fit for This Trial?
This trial is for people with Stage II-III non-small cell lung cancer (NSCLC) who have a high PD-L1 level (≥50%) and show no signs of cancer after chemotherapy and immunotherapy. They must be able to undergo surgery if needed, but can't join if they have the most advanced lymph node involvement (N3).Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Neoadjuvant Therapy
Participants receive neoadjuvant platinum-doublet chemotherapy and immunotherapy
Restaging
Intensified re-staging using invasive and non-invasive modalities to assess for complete clinical response
Randomization and Treatment
Participants with complete clinical response are randomized to observation or surgery
Follow-up
Long-term follow-up with assessments every 6-12 months up to 5 years
What Are the Treatments Tested in This Trial?
Interventions
- Observation without surgery
- Standard-of-care surgery
Trial Overview
The SAVED LUNG study tests whether patients with NSCLC who respond well to initial treatments need standard surgery or can just be observed without immediate surgery. It's a Phase I trial where participants are randomly chosen for either continued observation or surgery.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants undergo surveillance without surgery, including a low-dose CT scan of the thorax and upper abdomen, ECOG assessment, and physical examination every 3 months for the first 12 months. Additional ctDNA testing is performed 3 weeks post-randomization and at 6 months. Long-term follow-up includes similar assessments every 6-12 months up to 5 years.
Participants undergo surgery followed by the same surveillance schedule as Arm A. ctDNA testing is conducted 3 weeks post-surgery and again at 6 months. Surveillance includes low-dose CT scans, physical examinations, and ECOG assessments every 3 months for 12 months, with long-term monitoring at regular intervals up to 5 years.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor
Published Research Related to This Trial
Citations
Failure to Rescue and Lung Resections for Lung Cancer - PMC
Recent literature indicates that overall complication rates following lung resection vary between 25% and 40%, with major complications observed ...
Quality Surgical Care and Outcomes for Patients With Non ...
Lung cancer resections by more specialized surgeons have been associated with better outcomes. Specialization is also associated with improved ...
Lung Cancer Clinical and financial outcomes of pulmonary ...
Hospital safety-net status is associated with greater rates of complications and costs after lobectomy for lung cancer.
4.
massgeneral.org
massgeneral.org/surgery/thoracic-surgery/treatments-and-services/lung-cancer-patient-outcomesPatient Outcomes for Lung Cancer
Our rate of mortality (death) from lobectomy for lung cancer is lower than the STS and NIS databases. We also performed 77% of our Stage 1 cancer operations.
Ten-year clinical trial report finds radiation comparable to ...
Dr. Chang and his colleagues previously reported three- and five-year overall survival rates of 91% and 87% following SABR. They also reported ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.